샘플 요청 목록

 카트 문의
시장보고서
상품코드
1790236

북미의 임상시험 시장 규모, 점유율, 동향 분석 보고서 : 단계별, 시험 설계별, 적응증별, 서비스별, 스폰서별, 국가별, 부문별 예측(2025-2033년)

North America Clinical Trials Market Size, Share & Trends Analysis Report By Phase, By Study Design, By Indication, By Indication by Study Design, By Service, By Sponsor, By Country, And Segment Forecasts, 2025 - 2033
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

북미의 임상시험 시장 개요

북미의 임상시험 시장 규모는 2024년 430억 3,000만 달러로 평가되었습니다. 2033년에는 773억 2,000만 달러에 달하고, 2025-2033년 6.98% 성장할 것으로 예측됩니다. 시장 성장의 원동력은 학술연구기관의 탄탄한 생태계, 제약기업의 연구개발 자금 확대, 초기부터 후기까지 대량 검사를 지원하는 전문 개발업무수탁기관(CRO)입니다.

북미의 임상시험 시장은 고도로 발달된 연구 인프라와 임상 개발을 지속적으로 우선시하는 세계 제약, 생명공학, 의료기기 기업들의 집중에 의해 주도되고 있습니다. 메이요 클리닉, MD 앤더슨 암센터, 하버드대학교 의과대학 등 여러 학술 연구센터와 병원이 존재하여 초기 단계의 검사에 대한 혁신과 파트너십을 촉진하고 있습니다. 또한, 미국 FDA와 같은 규제기관은 임상시험계획(IND) 신청, 희귀질환 치료제 지정, 적응증 설계에 대한 확립된 프레임워크를 제공하여 진입장벽을 낮추고 임상 일정을 앞당기고 있습니다.

또한, 산업 이해관계자, 디지털 헬스 혁신가, 환자 옹호 단체 간의 협력이 증가하고 있습니다. 제약사들은 자체 R&D 파이프라인을 확장할 뿐만 아니라 CRO와 적극적으로 제휴하여 시험 설계, 시설 관리, 약사법 신청 등을 간소화하고 있습니다. 이러한 추세로 인해 스폰서는 데이터의 무결성이나 환자의 안전을 해치지 않고 일정을 앞당길 수 있습니다. 마찬가지로, 옹호 재단과 공중보건 캠페인의 지원을 받아 환자들의 인식과 교육이 높아지면서, 특히 종양이나 희귀질환과 같은 복잡한 영역에서 더 많은 환자들이 임상시험에 참여하게 되었습니다. 연방 정부의 가이드라인과 다양성 의무에 따라 보다 종합적인 등록 전략으로의 전환은 실제 집단을 더 잘 반영하는 임상 결과를 보장합니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 북미의 임상시험 시장 변수, 동향, 범위

  • 시장 계통 전망
    • 상위 시장 전망
    • 보조 시장 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
    • 시장 기회 분석
    • 시장이 해결해야 할 과제 분석
  • 연구개발비 분석
    • 주요 스폰서별 R&D 투자 분석(2021-2024년)
    • 벤처캐피털과 정부 자금조달 시나리오
  • 임상시험 설계 분석
  • 산업 생태계 분석
  • 기술
  • 가격 분석
  • 2024년 임상시험 건수 분석
    • 지역별 임상시험 건수(2024년)
    • 임상시험 건수(상별)(2024년)
    • 임상시험 건수(연구 디자인별)(2024년)
    • 주요 적응증별 임상시험 건수(2024년)
  • 임상시험 시장 분석 툴
    • Porter의 Five Forces 분석
    • SWOT 분석에 의한 PESTEL

제4장 북미의 임상시험 시장 : 단계별, 추정·동향 분석

  • 부문 대시보드
  • 북미의 임상시험 시장 : 단계 변동 분석
  • 단계별, 2021-2033년
  • 단계 I
  • 단계 II
  • 단계 III
  • 단계 IV

제5장 북미의 임상시험 시장 : 연구 설계별, 추정·동향 분석

  • 부문 대시보드
  • 북미의 임상시험 시장 : 연구 설계 변동 분석
  • 연구 설계별, 2021-2033년
  • 개입적
  • 관찰적
  • 확대 액세스

제6장 북미의 임상시험 시장 : 적응증별, 추정·동향 분석

  • 부문 대시보드
  • 북미의 임상시험 시장 : 적응증 변동 분석
  • 적응증별, 2021-2033년
  • 자가면역/염증
    • 류마티스 관절염
    • 다발성 경화증
    • 골관절염
    • 과민성 장증후군(IBS)
    • 기타
  • 통증 관리
    • 만성 통증
    • 급성 통증
  • 종양학
    • 혈액암
    • 고형 종양
    • 기타
  • 중추신경계 증상
    • 간질
    • 파킨슨병(PD)
    • 헌팅턴병
    • 뇌졸중
    • 외상성뇌손상(TBI)
    • 루게릭병(ALS)
    • 근육 재생
    • 기타
  • 당뇨병
  • 비만
  • 심혈관질환
  • 기타

제7장 북미의 임상시험 시장 : 연구 설계별, 적응증 추정·동향 분석

  • 부문 대시보드
  • 북미의 임상시험 시장 : 연구 설계 변동 분석
  • 연구 설계별, 연구 디자인별, 2021-2033년
  • 자가면역/염증
    • 개입 검사
    • 관찰 검사
    • 확대 액세스 검사
  • 통증 관리
    • 개입 검사
    • 관찰 검사
    • 확대 액세스 검사
  • 종양학
    • 개입 검사
    • 관찰 검사
    • 확대 액세스 검사
  • 중추신경계 증상
    • 개입 검사
    • 관찰 검사
    • 확대 액세스 검사
  • 당뇨병
    • 개입 검사
    • 관찰 검사
    • 확대 액세스 검사
  • 비만
    • 개입 검사
    • 관찰 검사
    • 확대 액세스 검사
  • 심혈관질환
    • 개입 검사
    • 관찰 검사
    • 확대 액세스 검사
  • 기타
    • 개입 검사
    • 관찰 검사
    • 확대 액세스 검사

제8장 북미의 임상시험 시장 : 서비스별, 추정·동향 분석

  • 부문 대시보드
  • 북미의 임상시험 시장 : 서비스 변동 분석
  • 서비스별, 2021-2033년
  • 프로토콜 설계
  • 부위 식별
  • 환자 모집
  • 실험실 서비스
  • 분석 검사 서비스
  • 임상시험 데이터 관리 서비스
  • 기타

제9장 북미의 임상시험 시장 : 스폰서별, 추정·동향 분석

  • 부문 대시보드
  • 북미의 임상시험 시장 : 스폰서 변동 분석
  • 스폰서별, 2021-2033년
  • 제약 바이오의약품 기업
  • 의료기기 기업
  • 기타

제10장 북미의 임상시험 시장 : 국가별, 추정·동향 분석

  • 국가별 전망
  • 북미의 임상시험 시장 : 국 변동 분석
  • 국가별, 2021-2033년
  • 북미
    • 미국
    • 캐나다
    • 멕시코

제11장 경쟁 구도

  • 기업 분류
    • 혁신기업
    • 마켓 리더
    • 신흥 참여 기업
  • 기업 시장 평가 분석, 2024년
  • 주요 기업 개요
    • Pfizer Inc.
    • Merck & Co., Inc.
    • AbbVie Inc.
    • Amgen Inc.
    • Bristol Myers Squibb
    • Gilead Sciences, Inc.
    • Eli Lilly and Company
    • Biogen Inc.
    • Moderna, Inc.
    • Labcorp
    • IQVIA, Inc.
    • Syneos Health
    • PAREXEL International Corporation
    • ICON Plc
    • Thermo Fisher Scientific Inc.
    • Charles River Laboratories International Inc.
    • Medpace Holdings, Inc.
    • Worldwide Clinical Trials
    • Clinipace Inc.
    • Fortrea
  • 기타 주요 시장 진출기업 리스트
LSH 25.08.25

North America Clinical Trials Market Summary

The North America clinical trials market size was estimated at USD 43.03 billion in 2024 and is projected to reach USD 77.32 billion by 2033, growing at a CAGR of 6.98% from 2025 to 2033. The market growth is driven by a robust ecosystem of academic research institutions, growing research and development funding by pharmaceutical companies, and specialized contract research organizations (CROs) that support a high volume of early-to late-phase studies.

The North America clinical trials market is propelled by a highly developed research infrastructure and a concentration of global pharmaceutical, biotechnology, and medical device companies that consistently prioritize clinical development. The presence of several academic research centers and hospitals such as the Mayo Clinic, MD Anderson Cancer Center, and Harvard Medical School is driving the innovation and partnerships in early-stage trials. Moreover, the regulatory agencies such as the U.S. FDA are offering well-established frameworks for Investigational New Drug (IND) applications, Orphan Drug Designations, and adaptive trial designs which is lowering the entry barriers and accelerating the clinical timeline.

Furthermore, increasing collaboration between industry stakeholders, digital health innovators, and patient advocacy groups. Pharmaceutical companies are not only expanding their in-house R&D pipelines but are also actively partnering with CROs to streamline study design, site management, and regulatory submissions. This trend allows sponsors to accelerate timelines without compromising on data integrity or patient safety. Similarly, rising patient awareness and education, often supported by advocacy foundations and public health campaigns has resulted in greater trial participation, particularly in complex areas such as oncology and rare diseases. The shift toward more inclusive enrollment strategies, supported by federal guidelines and diversity mandates, ensures that clinical outcomes better reflect real-world populations.

North America Clinical Trials Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the North America clinical trials market report based on phase, study design, indication, indication by study design, service, sponsor, and country:

  • Phase Outlook (Revenue, USD Million, 2021 - 2033)
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
  • Study Design Outlook (Revenue, USD Million, 2021 - 2033)
  • Interventional Trials
  • Observational Trials
  • Expanded Access Trials
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Autoimmune/Inflammation
    • Rheumatoid Arthritis
    • Multiple Sclerosis
    • Osteoarthritis
    • Irritable Bowel Syndrome (IBS)
    • Others
  • Pain Management
    • Chronic Pain
    • Acute Pain
  • Oncology
    • Blood Cancer
    • Solid Tumors
    • Others
  • CNS Conditions
    • Epilepsy
    • Parkinson's Disease (PD)
    • Huntington's Disease
    • Stroke
    • Traumatic Brain Injury (TBI)
    • Amyotrophic Lateral Sclerosis (ALS)
    • Muscle Regeneration
    • Others
  • Diabetes
  • Obesity
  • Cardiovascular Diseases
  • Others
  • Indication by Study Design Outlook (Revenue, USD Million, 2021 - 2033)
  • Autoimmune/Inflammation
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Pain Management
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Oncology
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • CNS Conditions
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Diabetes
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Obesity
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Cardiovascular Diseases
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Others
    • Interventional Trials
    • Observational Trials
    • Expanded Access Trials
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Protocol Designing
  • Site Identification
  • Patient Recruitment
  • Laboratory Services
  • Analytical Testing Services
  • Clinical Trial Data Management Services
  • Others
  • Sponsor Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical & Biopharmaceutical Companies
  • Medical Device Companies
  • Others
  • Country Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Value chain based analysis (Model 2)
    • 1.7.3. Multivariate Analysis (Model 3)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. North America Clinical Trials Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. R&D Spending Analysis
    • 3.3.1. R&D Investment Analysis, by Key Sponsors (2021-2024)
    • 3.3.2. Venture Capital & Government Funding Scenario
  • 3.4. Clinical Trials Design Analysis
  • 3.5. Industry Ecosystem Analysis
  • 3.6. Technology Landscape
  • 3.7. Pricing Analysis
  • 3.8. Clinical Trial Volume Analysis, 2024
    • 3.8.1. Total Number of Clinical Trials, By Region (2024)
    • 3.8.2. Total Number of Clinical Trials, By Phase (2024)
    • 3.8.3. Total Number of Clinical Trials, By Study Design (2024)
    • 3.8.4. Total Number of Clinical Trials, By Key Indication (2024)
  • 3.9. Clinical Trials Market Analysis Tools
    • 3.9.1. Porter's Five Forces Analysis
    • 3.9.2. PESTEL by SWOT Analysis

Chapter 4. North America Clinical Trials Market: Phase Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. North America Clinical Trials Market: Phase Movement Analysis
  • 4.3. North America Clinical Trials Market Estimates and Forecasts, by Phase, 2021 - 2033 (USD Million)
  • 4.4. Phase I
    • 4.4.1. Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Phase II
    • 4.5.1. Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Phase III
    • 4.6.1. Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Phase IV
    • 4.7.1. Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. North America Clinical Trials Market: Study Design Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. North America Clinical Trials Market: Study Design Movement Analysis
  • 5.3. North America Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • 5.4. Interventional
    • 5.4.1. Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Observational
    • 5.5.1. Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Expanded Access
    • 5.6.1. Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. North America Clinical Trials Market: Indication Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. North America Clinical Trials Market: Indication Movement Analysis
  • 6.3. North America Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • 6.4. Autoimmune/Inflammation
    • 6.4.1. Autoimmune/Inflammation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.2. Rheumatoid Arthritis
      • 6.4.2.1. Rheumatoid Arthritis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Multiple Sclerosis
      • 6.4.3.1. Multiple Sclerosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Osteoarthritis
      • 6.4.4.1. Osteoarthritis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.5. Irritable Bowel Syndrome (IBS)
      • 6.4.5.1. Irritable Bowel Syndrome (IBS) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Pain Management
    • 6.5.1. Pain Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. Chronic Pain
      • 6.5.2.1. Chronic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Acute Pain
      • 6.5.3.1. Acute Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Oncology
    • 6.6.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Blood Cancer
      • 6.6.2.1. Blood Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. Solid Tumors
      • 6.6.3.1. Solid Tumors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. Others
      • 6.6.4.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. CNS Conditions
    • 6.7.1. CNS Conditions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Epilepsy
      • 6.7.2.1. Epilepsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Parkinson's Disease (PD)
      • 6.7.3.1. Parkinson's Disease (PD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.4. Huntington's Disease
      • 6.7.4.1. Huntington's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.5. Stroke
      • 6.7.5.1. Stroke Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.6. Traumatic Brain Injury (TBI)
      • 6.7.6.1. Traumatic Brain Injury (TBI) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.7. Amyotrophic Lateral Sclerosis (ALS)
      • 6.7.7.1. Amyotrophic Lateral Sclerosis (ALS) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.8. Muscle Regeneration
      • 6.7.8.1. Muscle Regeneration Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.9. Others
      • 6.7.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Diabetes
    • 6.8.1. Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.9. Obesity
    • 6.9.1. Obesity Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.10. Cardiovascular Diseases
    • 6.10.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.11. Others
    • 6.11.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. North America Clinical Trials Market: Indication by Study Design Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. North America Clinical Trials Market: Indication by Study Design Movement Analysis
  • 7.3. North America Clinical Trials Market Estimates and Forecasts, by Indication by Study Design, 2021 - 2033 (USD Million)
  • 7.4. Autoimmune/Inflammation
    • 7.4.1. Autoimmune/Inflammation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. Interventional Trials
      • 7.4.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Observational Trials
      • 7.4.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Expanded Access Trials
      • 7.4.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Pain Management
    • 7.5.1. Pain Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Interventional Trials
      • 7.5.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Observational Trials
      • 7.5.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. Expanded Access Trials
      • 7.5.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Oncology
    • 7.6.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Interventional Trials
      • 7.6.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Observational Trials
      • 7.6.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. Expanded Access Trials
      • 7.6.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. CNS Conditions
    • 7.7.1. CNS Conditions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Interventional Trials
      • 7.7.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Observational Trials
      • 7.7.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.4. Expanded Access Trials
      • 7.7.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Diabetes
    • 7.8.1. Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. Interventional Trials
      • 7.8.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Observational Trials
      • 7.8.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. Expanded Access Trials
      • 7.8.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9. Obesity
    • 7.9.1. Obesity Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.9.2. Interventional Trials
      • 7.9.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.9.3. Observational Trials
      • 7.9.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.9.4. Expanded Access Trials
      • 7.9.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.10. Cardiovascular Diseases
    • 7.10.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.10.2. Interventional Trials
      • 7.10.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.10.3. Observational Trials
      • 7.10.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.10.4. Expanded Access Trials
      • 7.10.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.11. Others
    • 7.11.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.11.2. Interventional Trials
      • 7.11.2.1. Interventional Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.11.3. Observational Trials
      • 7.11.3.1. Observational Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.11.4. Expanded Access Trials
      • 7.11.4.1. Expanded Access Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. North America Clinical Trials Market: Service Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. North America Clinical Trials Market: Service Movement Analysis
  • 8.3. North America Clinical Trials Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
  • 8.4. Protocol Designing
    • 8.4.1. Protocol Designing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Site Identification
    • 8.5.1. Site Identification Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Patient Recruitment
    • 8.6.1. Patient Recruitment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Laboratory Services
    • 8.7.1. Laboratory Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Analytical Testing Services
    • 8.8.1. Analytical Testing Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.9. Clinical Trial Data Management Services
    • 8.9.1. Clinical Trial Data Management Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.10. Others
    • 8.10.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. North America Clinical Trials Market: Sponsor Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. North America Clinical Trials Market: Sponsor Movement Analysis
  • 9.3. North America Clinical Trials Market Estimates and Forecasts, by Sponsor, 2021 - 2033 (USD Million)
  • 9.4. Pharmaceutical & Biopharmaceutical Companies
    • 9.4.1. Pharmaceutical & Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5. Medical Device Companies
    • 9.5.1. Medical Device Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6. Others
    • 9.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. North America Clinical Trials Market: Country Estimates & Trend Analysis

  • 10.1. Country Outlook
  • 10.2. North America Clinical Trials Market: Country Movement Analysis
  • 10.3. North America Clinical Trials Market Estimates and Forecasts, by Country, 2021 - 2033 (USD Million)
  • 10.4. North America
    • 10.4.1. North America Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.4.2. U.S.
      • 10.4.2.1. Key Country Dynamics
      • 10.4.2.2. Competitive Scenario
      • 10.4.2.3. Regulatory Framework
      • 10.4.2.4. U.S. Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.4.3. Canada
      • 10.4.3.1. Key Country Dynamics
      • 10.4.3.2. Competitive Scenario
      • 10.4.3.3. Regulatory Framework
      • 10.4.3.4. Canada Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 10.4.4. Mexico
      • 10.4.4.1. Key Country Dynamics
      • 10.4.4.2. Competitive Scenario
      • 10.4.4.3. Regulatory Framework
      • 10.4.4.4. Mexico Clinical Trials Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Company Categorization
    • 11.1.1. Innovators
    • 11.1.2. Market Leaders
    • 11.1.3. Emerging Players
  • 11.2. Company Market Assessment Analysis, 2024
  • 11.3. Key Company Profiles
    • 11.3.1. Pfizer Inc.
      • 11.3.1.1. Company Overview
      • 11.3.1.2. Financial Performance
      • 11.3.1.3. Service Benchmarking
      • 11.3.1.4. Strategic Initiatives
    • 11.3.2. Merck & Co., Inc.
      • 11.3.2.1. Company Overview
      • 11.3.2.2. Financial Performance
      • 11.3.2.3. Service Benchmarking
      • 11.3.2.4. Strategic Initiatives
    • 11.3.3. AbbVie Inc.
      • 11.3.3.1. Company Overview
      • 11.3.3.2. Financial Performance
      • 11.3.3.3. Service Benchmarking
      • 11.3.3.4. Strategic Initiatives
    • 11.3.4. Amgen Inc.
      • 11.3.4.1. Company Overview
      • 11.3.4.2. Financial Performance
      • 11.3.4.3. Service Benchmarking
      • 11.3.4.4. Strategic Initiatives
    • 11.3.5. Bristol Myers Squibb
      • 11.3.5.1. Company Overview
      • 11.3.5.2. Financial Performance
      • 11.3.5.3. Service Benchmarking
      • 11.3.5.4. Strategic Initiatives
    • 11.3.6. Gilead Sciences, Inc.
      • 11.3.6.1. Company Overview
      • 11.3.6.2. Financial Performance
      • 11.3.6.3. Service Benchmarking
      • 11.3.6.4. Strategic Initiatives
    • 11.3.7. Eli Lilly and Company
      • 11.3.7.1. Company Overview
      • 11.3.7.2. Financial Performance
      • 11.3.7.3. Service Benchmarking
      • 11.3.7.4. Strategic Initiatives
    • 11.3.8. Biogen Inc.
      • 11.3.8.1. Company Overview
      • 11.3.8.2. Financial Performance
      • 11.3.8.3. Service Benchmarking
      • 11.3.8.4. Strategic Initiatives
    • 11.3.9. Moderna, Inc.
      • 11.3.9.1. Company Overview
      • 11.3.9.2. Financial Performance
      • 11.3.9.3. Service Benchmarking
      • 11.3.9.4. Strategic Initiatives
    • 11.3.10. Labcorp
      • 11.3.10.1. Company Overview
      • 11.3.10.2. Financial Performance
      • 11.3.10.3. Service Benchmarking
      • 11.3.10.4. Strategic Initiatives
    • 11.3.11. IQVIA, Inc.
      • 11.3.11.1. Company Overview
      • 11.3.11.2. Financial Performance
      • 11.3.11.3. Service Benchmarking
      • 11.3.11.4. Strategic Initiatives
    • 11.3.12. Syneos Health
      • 11.3.12.1. Company Overview
      • 11.3.12.2. Financial Performance
      • 11.3.12.3. Service Benchmarking
      • 11.3.12.4. Strategic Initiatives
    • 11.3.13. PAREXEL International Corporation
      • 11.3.13.1. Company Overview
      • 11.3.13.2. Financial Performance
      • 11.3.13.3. Service Benchmarking
      • 11.3.13.4. Strategic Initiatives
    • 11.3.14. ICON Plc
      • 11.3.14.1. Company Overview
      • 11.3.14.2. Financial Performance
      • 11.3.14.3. Service Benchmarking
      • 11.3.14.4. Strategic Initiatives
    • 11.3.15. Thermo Fisher Scientific Inc.
      • 11.3.15.1. Company Overview
      • 11.3.15.2. Financial Performance
      • 11.3.15.3. Service Benchmarking
      • 11.3.15.4. Strategic Initiatives
    • 11.3.16. Charles River Laboratories International Inc.
      • 11.3.16.1. Company Overview
      • 11.3.16.2. Financial Performance
      • 11.3.16.3. Service Benchmarking
      • 11.3.16.4. Strategic Initiatives
    • 11.3.17. Medpace Holdings, Inc.
      • 11.3.17.1. Company Overview
      • 11.3.17.2. Financial Performance
      • 11.3.17.3. Service Benchmarking
      • 11.3.17.4. Strategic Initiatives
    • 11.3.18. Worldwide Clinical Trials
      • 11.3.18.1. Company Overview
      • 11.3.18.2. Financial Performance
      • 11.3.18.3. Service Benchmarking
      • 11.3.18.4. Strategic Initiatives
    • 11.3.19. Clinipace Inc.
      • 11.3.19.1. Company Overview
      • 11.3.19.2. Financial Performance
      • 11.3.19.3. Service Benchmarking
      • 11.3.19.4. Strategic Initiatives
    • 11.3.20. Fortrea
      • 11.3.20.1. Company Overview
      • 11.3.20.2. Financial Performance
      • 11.3.20.3. Service Benchmarking
      • 11.3.20.4. Strategic Initiatives
  • 11.4. List of Other Key Market Players
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제